DEXMEDETOMIDINE FOR SEDATION IN CHILDREN – A NARRATIVE REVIEW OF CLINICAL EVIDENCE, SAFETY CONSIDERATIONS, AND EMERGING THERAPEUTIC ROLES
Authors:
- Gabriela FariaGFGabriela Faria
- Anna WyżykowskaAWAnna Wyżykowska
- Monika MaruszakMMMonika Maruszak
- Julia GrygorowiczJGJulia Grygorowicz
- Michał NiedzielaMNMichał Niedziela
- Monika Sas-WyżykowskaMSMonika Sas-Wyżykowska
- Alina MykhalevychAMAlina Mykhalevych
- Aliaksandr KryshtofikAKAliaksandr Kryshtofik
- Aleksandra BlachucikABAleksandra Blachucik
Open Access
- 7 September 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Abstract
Dexmedetomidine is a highly selective alfa2-adrenergic agonist increasingly used in pediatric anesthesia and intensive care because of its unique sedative profile and minimal respiratory depressive effects. This narrative summarizes current evidence regarding the pharmacology, pharmacokinetics, clinical efficacy, safety profile and emerging applications of dexmedetomidine in pediatric patients. Current literature supports the use of dexmedetomidine in multiple clinical settings, including procedural sedation, perioperative management, and pediatric intensive care. The drug has demonstrated efficacy in reducing opioid requirements, preventing emergence agitation and delirium, and providing effective sedation while preserving spontaneous respiration. However, its use remains associated with dose-dependent cardiovascular adverse effects, particularly bradycardia and hypotension, requiring individualized dosing and careful monitoring, especially in neonates and infants due to age-related pharmacokinetic variability. Emerging evidence suggests potential neuroprotective and organ-protective properties, although robust pediatric clinical data remains limited. Novel applications and alternative administration routes continue to expand the potential role of dexmedetomidine in pediatric practice. Overall, dexmedetomidine represents a versatile and valuable sedative agent in pediatric medicine, though further high-quality studies are needed to optimize dosing strategies and better define long-term safety outcomes.Keywords
This publication has 27 references indexed in Scilit:
- A systematic review of dexmedetomidine pharmacology in pediatric patientsClinical and Translational Science, 2024
- Optimizing Pediatric Sedation: Evaluating Remimazolam and Dexmedetomidine for Safety and Efficacy in Clinical PracticePediatric Drugs, 2024
- Best Evidence-Based Dosing Recommendations for Dexmedetomidine for Premedication and Procedural Sedation in Pediatrics: Outcome of a Risk-Benefit Analysis By the Dutch Pediatric FormularyPediatric Drugs, 2022
- Dexmedetomidine – An emerging option for sedation in neonatal patientsJournal of Perinatology, 2022
- A Comparison of Dexmedetomidine and Propofol on Emergence Delirium in Children Undergoing Cleft Palate Surgery With Sevoflurane-Based AnesthesiaJournal of Craniofacial Surgery, 2021
- Age-Specific Dose Regimens of Dexmedetomidine for Pediatric Patients in Intensive Care Following Elective Surgery: A Phase 3, Multicenter, Open-Label Clinical Trial in JapanPediatric Critical Care Medicine, 2021
- Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologistsEuropean Journal of Clinical Pharmacology, 2020
- Systematic review and meta‐analysis found that intranasal dexmedetomidine was a safe and effective sedative drug during paediatric procedural sedationActa Paediatrica, 2020
- Dexmedetomidine for Prolonged Sedation in the PICU: A Systematic Review and Meta-Analysis*Pediatric Critical Care Medicine, 2020
- Efficacy and Safety of Dexmedetomidine for Prolonged Sedation in the PICU: A Prospective Multicenter Study (PROSDEX)*Pediatric Critical Care Medicine, 2020